Liquid Biopsy Across the Drug Lifecycle: Discovery, Differentiation & Adoption
- Showing how Amgen leverages ctDNA and other modalities across discovery, clinical development, and commercialization to accelerate differentiation, regulatory approvals, and market adoption
- Highlighting case studies where ctDNA and liquid biopsy analyses informed dose selection, early efficacy readouts, and patient stratification, directly supporting faster decisionmaking and clinical success
- Discussing how Amgen generates the biomarker evidence base needed for regulators, payers, and clinicians to embrace liquid biopsy as a standard tool in advancing precision medicine